South Korea · Delayed Price · Currency is KRW GL Pharm Tech Statistics
Total Valuation
GL Pharm Tech has a market cap or net worth of KRW 65.22 billion. The enterprise value is 82.64 billion.
| Market Cap | 65.22B |
| Enterprise Value | 82.64B |
Important Dates
The next estimated earnings date is Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GL Pharm Tech has 15.51 million shares outstanding. The number of shares has increased by 71.51% in one year.
| Current Share Class | 15.51M |
| Shares Outstanding | 15.51M |
| Shares Change (YoY) | +71.51% |
| Shares Change (QoQ) | +425.65% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 14.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.71 |
| PB Ratio | 3.28 |
| P/TBV Ratio | 3.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.16 |
| EV / EBITDA | 50.23 |
| EV / EBIT | 161.96 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 1.05.
| Current Ratio | 0.98 |
| Quick Ratio | 0.46 |
| Debt / Equity | 1.05 |
| Debt / EBITDA | 15.36 |
| Debt / FCF | -6.24 |
| Interest Coverage | 0.34 |
Financial Efficiency
Return on equity (ROE) is -0.54% and return on invested capital (ROIC) is 0.60%.
| Return on Equity (ROE) | -0.54% |
| Return on Assets (ROA) | 0.30% |
| Return on Invested Capital (ROIC) | 0.60% |
| Return on Capital Employed (ROCE) | 0.82% |
| Weighted Average Cost of Capital (WACC) | 5.54% |
| Revenue Per Employee | 1.16B |
| Profits Per Employee | -3.25M |
| Employee Count | 33 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 2.16 |
Taxes
In the past 12 months, GL Pharm Tech has paid 63.51 million in taxes.
| Income Tax | 63.51M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.73% in the last 52 weeks. The beta is 0.41, so GL Pharm Tech's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | -28.73% |
| 50-Day Moving Average | 4,331.80 |
| 200-Day Moving Average | 5,274.83 |
| Relative Strength Index (RSI) | 52.57 |
| Average Volume (20 Days) | 88,373 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GL Pharm Tech had revenue of KRW 38.21 billion and -107.11 million in losses. Loss per share was -1.31.
| Revenue | 38.21B |
| Gross Profit | 15.33B |
| Operating Income | 224.21M |
| Pretax Income | -43.60M |
| Net Income | -107.11M |
| EBITDA | 1.36B |
| EBIT | 224.21M |
| Loss Per Share | -1.31 |
Balance Sheet
The company has 3.46 billion in cash and 20.88 billion in debt, with a net cash position of -17.42 billion or -1,123.11 per share.
| Cash & Cash Equivalents | 3.46B |
| Total Debt | 20.88B |
| Net Cash | -17.42B |
| Net Cash Per Share | -1,123.11 |
| Equity (Book Value) | 19.89B |
| Book Value Per Share | 243.96 |
| Working Capital | -442.35M |
Cash Flow
In the last 12 months, operating cash flow was -354.85 million and capital expenditures -2.99 billion, giving a free cash flow of -3.35 billion.
| Operating Cash Flow | -354.85M |
| Capital Expenditures | -2.99B |
| Depreciation & Amortization | 1.13B |
| Net Borrowing | 5.66B |
| Free Cash Flow | -3.35B |
| FCF Per Share | -215.84 |
Margins
Gross margin is 40.13%, with operating and profit margins of 0.59% and -0.28%.
| Gross Margin | 40.13% |
| Operating Margin | 0.59% |
| Pretax Margin | -0.11% |
| Profit Margin | -0.28% |
| EBITDA Margin | 3.56% |
| EBIT Margin | 0.59% |
| FCF Margin | n/a |
Dividends & Yields
GL Pharm Tech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -71.51% |
| Shareholder Yield | -71.51% |
| Earnings Yield | -0.16% |
| FCF Yield | -5.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 11, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Aug 11, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
GL Pharm Tech has an Altman Z-Score of 1.91 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.91 |
| Piotroski F-Score | 3 |